Brian I. Rini
Impact in
- Pulmonary and Respiratory Medicine top 0.01%
- Renal cell carcinoma treatment
- Ferroptosis and cancer prognosis
- Cancer Research top 0.05%
- Cancer Genomics and Diagnostics
- Cancer, Hypoxia, and Metabolism
Papers in
-
- Renal cell carcinoma treatment 401
- Cancer Research 111
- Cancer Genomics and Diagnostics 86
- Co-authors
- Bernard J. Escudier (56 shared papers)Steven C. Campbell (27 shared papers)Eric Jay Small (36 shared papers)Robert John Motzer (68 shared papers)Toni K. Choueiri (89 shared papers)Ronald M. Bukowski (39 shared papers)Michael B. Atkins (42 shared papers)James H. Finke (26 shared papers)
- Journals
- Annals of Oncology (59 papers)Clinical Genitourinary Cancer (44 papers)Journal of Clinical Oncology (33 papers)Cancer (32 papers)Clinical Cancer Research (28 papers)
- Partner nations
- United StatesFranceUnited Kingdom
In The Last Decade
Brian I. Rini
582 papers receiving 58.8k citations
Brian I. Rini's Hit Papers
Peers
Comparison fields: 5 of 163
- Pulmonary and Respiratory Medicine 34.2k
- Cancer Research 12.8k
- Oncology 19.3k
- Immunology 6.0k
- Molecular Biology 18.9k
Countries citing papers authored by Brian I. Rini
This map shows the geographic impact of Brian I. Rini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian I. Rini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian I. Rini more than expected).
Fields of papers citing papers by Brian I. Rini
This network shows the impact of papers produced by Brian I. Rini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian I. Rini. The network helps show where Brian I. Rini may publish in the future.
Co-authors
The 25 scholars most cited alongside Brian I. Rini, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 598 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma Hit paper breakdown → | 2018 | 3643 |
| 2 | Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma Hit paper breakdown → | 2019 | 2634 |
| 3 | Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma Hit paper breakdown → | 2019 | 1971 |
| 4 | Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study Hit paper breakdown → | 2009 | 1737 |
| 5 | Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial Hit paper breakdown → | 2011 | 1544 |
| 6 | Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma Hit paper breakdown → | 2005 | 1379 |
| 7 | Renal cell carcinoma Hit paper breakdown → | 2009 | 1352 |
| 8 | Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study Hit paper breakdown → | 2020 | 1331 |
| 9 | Sunitinib in Patients With Metastatic Renal Cell Carcinoma Hit paper breakdown → | 2006 | 1025 |
| 10 | Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma Hit paper breakdown → | 2018 | 1011 |
| 11 | Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma Hit paper breakdown → | 2015 | 1004 |
| 12 | Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial Hit paper breakdown → | 2014 | 928 |
| 13 | External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study Hit paper breakdown → | 2013 | 827 |
| 14 | Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial Hit paper breakdown → | 2019 | 817 |
| 15 | Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial Hit paper breakdown → | 2016 | 778 |
| 16 | Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206 Hit paper breakdown → | 2008 | 753 |
| 17 | Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients Hit paper breakdown → | 2009 | 744 |
| 18 | Treatment of renal cell carcinoma: Current status and future directions Hit paper breakdown → | 2017 | 654 |
| 19 | Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206 Hit paper breakdown → | 2010 | 645 |
| 20 | Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial Hit paper breakdown → | 2019 | 643 |
About Brian I. Rini
Brian I. Rini is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research, Oncology, Molecular Biology and Immunology, having authored 598 papers that have together received 60.1k indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (401 papers), Renal and related cancers (113 papers), Cancer Genomics and Diagnostics (86 papers), Cancer Immunotherapy and Biomarkers (76 papers), Pancreatic and Hepatic Oncology Research (36 papers), Bladder and Urothelial Cancer Treatments (27 papers), Economic and Financial Impacts of Cancer (22 papers) and CAR-T cell therapy research (21 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (34.2k citations), Cancer Research (12.8k citations), Oncology (19.3k citations), Immunology (6.0k citations) and Molecular Biology (18.9k citations). Brian I. Rini has collaborated with scholars based in United States, France and United Kingdom. Frequent co-authors include Bernard J. Escudier, Steven C. Campbell, Eric Jay Small, Robert John Motzer, Toni K. Choueiri, Ronald M. Bukowski, Michael B. Atkins, James H. Finke, David F. McDermott and Pedro Coelho Barata. Their work appears in journals such as Annals of Oncology, Clinical Genitourinary Cancer, Journal of Clinical Oncology, Cancer and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.